RIGEL PHARMACEUTICALS, INC. Available-for-sale Securities, Gross Unrealized Loss
RIGEL PHARMACEUTICALS, INC. (RIGL) reported Available-for-sale Securities, Gross Unrealized Loss of $27.00 thousand for the 12-month period ending 2018-12-31, per its 10-K filed 2019-02-28.
Discontinued › Expense Statement › Operating Expenses
us-gaap:AvailableForSaleSecuritiesGrossUnrealizedLoss · last filed 2019-02-28
- RIGEL PHARMACEUTICALS, INC. available-for-sale securities, gross unrealized loss for fiscal 2018 was $27.00K, a 67.47% decline from fiscal 2017.
- RIGEL PHARMACEUTICALS, INC. available-for-sale securities, gross unrealized loss for fiscal 2017 was $83.00K, a 260.87% increase from fiscal 2016.
- RIGEL PHARMACEUTICALS, INC. available-for-sale securities, gross unrealized loss for fiscal 2016 was $23.00K, a 58.93% decline from fiscal 2015.
- RIGEL PHARMACEUTICALS, INC. available-for-sale securities, gross unrealized loss for fiscal 2015 was $56.00K, a 75.00% increase from fiscal 2014.
| Period end | Available-for-sale Securities, Gross Unrealized Loss 12 month |
|---|---|
| 2018-12-31 | $27.00K 10-K · filed 2019-02-28 |
| 2017-12-31 | $83.00K 10-K · filed 2019-02-28 |
| 2016-12-31 | $23.00K 10-K · filed 2018-03-06 |
| 2015-12-31 | $56.00K 10-K · filed 2017-03-07 |
| 2014-12-31 | $32.00K 10-K · filed 2016-03-08 |
| 2013-12-31 | $17.00K 10-K · filed 2015-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 |